Delaware Medicaid spending on GLP-1 drugs

How much did Delaware Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $21.4 million for GLP-1 drugs paid through Delaware Medicaid in 2025, across at least 55,674 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 104 rows of 218, so these figures are floors.

Pharmacies were reimbursed at least $5.0 million for GLP-1 drugs paid through Delaware Medicaid in 2026 (quarter 1 only, as posted so far), across at least 10,855 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 31 rows of 58, so these figures are floors.

By year and ingredient

2020at least $1,925,124No dataat least $966,659at least $602,098at least $2,286,404at least $720at least $1,304at least $5,782,309
2021at least $5,385,277No dataat least $1,350,515at least $2,706,735at least $683,547at least $6,502Suppressedat least $10,132,576
2022at least $8,468,046at least $7,539at least $1,189,176at least $4,944,345at least $251,567$8,706Suppressedat least $14,869,380
2023at least $16,083,709at least $152,270at least $851,030at least $7,298,756at least $125,393at least $5,956Suppressedat least $24,517,115
2024at least $19,379,048at least $354,836at least $137,749at least $4,182,063at least $78,760at least $3,461Suppressedat least $24,135,916
2025at least $17,631,684at least $396,717at least $8,787at least $3,308,565at least $9,165SuppressedSuppressedat least $21,354,918
2026 (Q1)at least $4,215,831at least $74,856Suppressedat least $744,872No dataSuppressedSuppressedat least $5,035,559

By product, 2025

Ozempicat least $16,704,371at least 17,13420 of 32
Rybelsus$401,0144140 of 12
Wegovyat least $526,298at least 18,7658 of 28
Mounjaroat least $202,767at least 2,98713 of 37
Zepboundat least $193,950at least 12,78421 of 45
Liraglutide (generic name listing)SuppressedSuppressed15 of 15
Saxendaat least $8,787at least 981 of 4
VictozaSuppressedSuppressed7 of 7
Trulicityat least $3,308,565at least 3,48113 of 31
Bydureonat least $9,165at least 111 of 2
SoliquaSuppressedSuppressed4 of 4
XultophySuppressedSuppressed1 of 1

By quarter, 2025

Q1 2025at least $5,480,217at least 12,40127 of 56
Q2 2025at least $5,336,600at least 13,49723 of 51
Q3 2025at least $5,351,702at least 14,46025 of 54
Q4 2025at least $5,186,398at least 15,31629 of 57

By quarter, 2026 (posted so far)

Q1 2026at least $5,035,559at least 10,85531 of 58

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.